Türk Göğüs Kalp Damar Cerrahisi Dergisi

Our medical research library holds 6 studies published in Türk Göğüs Kalp Damar Cerrahisi Dergisi (2019–2026). Each entry links to the study's record on PubMed and, where there is one, to the publisher's page and a free full text. 6 have an abstract, the authors' own summary as PubMed records it: open "Abstract" to read it.

About the journal

• Publisher: Galenos Publishing House
• Published: 1999 to the present, Turkey
• Language: English
• ISSN: 1301-5680 (print), 2149-8156 (electronic)
• Continues: Göǧüs Kalp-damar Cerrahisi
• Its record in the NLM Catalog

2020s

• Factors affecting prognosis in patients diagnosed with epithelioid pleural mesothelioma who underwent surgery. N. Akanil Fener, N. Ünver, H.N. Ürer, et al. 2026;34(2):198-206. PubMed · Publisher · Free full text

  Abstract

  Background: To examine how pathological variables affect prognosis in patients undergoing surgery for epithelioid pleural mesothelioma (PM).

  Methods: The study examined 64 patients treated surgery for PM between January 2007 and October 2019, retrospectively. Clinicopathological variables including age, surgical procedure, tumor stage, and detailed histopathological features (nuclear atypia, mitotic count, necrosis, nuclear grading, and tumor grade) were evaluated. Overall survival was analyzed using Kaplan-Meier and Cox proportional hazards regression models. To avoid multicollinearity among interrelated pathological parameters, two separate multivariate Cox models were constructed.

  Results: The 5-year survival rate was 8 percent, compared to 62 percent in the first year. Individuals 65 and older had no 5-year survival, whereas patients 65 and younger had a rate of 11 percent (p=0.046). In comparison to groups with mild and moderately high mitotic scores, those with a high mitotic score (p=0.019) had significantly lower median survival and 5-year survival rates. Variables (p<0.15) included in the univariate survival analysis were patients who 65 years and older, type of operation, mitosis, necrosis, tumor stage, nuclear grading, and grade of mesotheliomas. In multivariate analysis, high nuclear grade (Model 1: Hazard ratio [HR]=2.48, 95% confidence interval [CI]: 1.09-5.62, p=0.030) and high tumor grade (Model 2: HR=2.36, 95% CI: 1.05-5.31, p=0.037) were independently associated with worse overall survival.

  Conclusion: Pathological grading, represented by either nuclear grade or tumor grade, is the strongest independent prognostic factor for survival in patients with epithelioid PM.

  Copyright© 2026 The Author(s). Published by Galenos Publishing House on behalf of Turkish Society of Cardiovascular Surgery and Turkish Thoracic Surgery Association.

• Prognostic effect of systemic inflammation in patients undergoing cytoreductive surgery and hyperthermic intrathoracic chemotherapy. A.K. Tekneci, H. Yavuz, G. Keçeci Özgür, et al. 2026;34(2):192-197. PubMed · Publisher · Free full text

  Abstract

  Background: To investigate prognostic significance of systemic inflammation-related parameters in patients undergoing cytoreductive surgery and hyperthermic intrathoracic chemotherapy for malignant pleural mesothelioma (MPM).

  Methods: Data from 55 patients were analyzed retrospectively. Demographic characteristics, survival outcomes and inflammation-related parameters (neutrophil/lymphocyte ratio [NLR], platelet/lymphocyte ratio [PLR], lymphocyte/monocyte ratio [LMR] and pan-immune inflammation value [PIV]) were evaluated.

  Results: Overall survival (OS) was 61.26±13.03 (3-79) months in patients with low NLR, whereas, it was 23.18±3.53 (1-147) months in patients with high NLR (p=0.012). No statistically significant differences in OS were detected according to LMR, PLR and PIV. In addition, OS was 24.40±4.91 (3-92) months in men and 52.8±10.92 (1-147) months in women (p=0.031).

  Conclusion: In this study, NLR was found to be associated with survival in agreement with the existing literature, thereby distinguishing it from other inflammatory markers as a prognostic factor. In clinical practice, predicting patient prognosis based on pre-treatment NLR may provide a valuable guidance for treatment decision-making.

  Copyright© 2026 The Author(s). Published by Galenos Publishing House on behalf of Turkish Society of Cardiovascular Surgery and Turkish Thoracic Surgery Association.

• Prognostic factors and the prognostic role of inflammation indices in malignant pleural mesothelioma. S. Ebinç, Z. Oruç, Z. Kalkan, et al. 2023;31(1):105-115. PubMed · Publisher · Free full text

  Abstract

  Background: In this study, we aimed to investigate the prognostic factors of malignant pleural mesothelioma and the prognostic value of inflammation indices in malignant pleural mesothelioma.

  Methods: Between January 2002 and December 2019, a total of 132 patients (74 males, 58 females; mean age: 55 years; range, 31 to 79 years) diagnosed with malignant pleural mesothelioma were retrospectively analyzed. Patients" demographic data and laboratory results were recorded. The prognostic value of the following five inflammation indices was evaluated: neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, advanced lung cancer inflammation index, C-reactive protein/albumin ratio, and prognostic nutritional index.

  Results: Of all patients, 81% (n=107) were aged 65 or older and 61.4% (n=81) had an epithelioid histology. Of 12 variables examined in the multivariate analysis for their relationship with survival, age ≥65 years, non-epithelioid subtype, and prognostic nutritional index <40 were found to be poor prognostic factors. Based on the score constructed from these factors, the good prognostic group (score 0-1) had a median overall survival of 21 months and a one-year survival rate of 77.9%, while the poor prognostic group (score 2-3) had a median overall survival of nine months and a one-year survival rate of 29.7%.

  Conclusion: Our study results indicate that age ≥65 years, prognostic nutritional index <40, and non-epithelioid histological subtype are poor prognostic factors of malignant pleural mesothelioma.

  Copyright © 2023, Turkish Society of Cardiovascular Surgery.

• Survival of pleurectomy-decortication and hyperthermic chemotherapy in mesothelioma. A.G. Ergönül, S. Aydın, S. Kahraman Aydın, et al. 2023;31(3):381-387. PubMed · Publisher · Free full text

  Abstract

  Background: This study aims to evaluate overall survival, diseasefree survival, and prognostic factors in patients undergoing pleurectomy-decortication and hyperthermic intrathoracic chemotherapy with the diagnosis of malignant pleural mesothelioma.

  Methods: Between January 2020 and November 2021, a total of 53 patients (27 males, 26 females; mean age: 58.1±1.3 years; range, 39 to 81 years) who underwent pleurectomy-decortication and hyperthermic intrathoracic chemotherapy with the diagnosis of malignant pleural mesothelioma were retrospectively analyzed. Data including characteristics, comorbidities, postoperative complications, recurrence and mortality status of the patients were recorded. Overall survival and disease-free survival and prognostic factors were evaluated.

  Results: The median disease-free survival was 11.67 months and the median overall survival was 24.60 months. The median disease-free survival was 8.80 months in men and 13.17 months in women, indicating a statistically significant difference as it showed that recurrence was detected earlier in male patients (p=0.037). The median disease-free survival and overall survival was 6.13 months and 11.70 in cases diagnosed with biphasic mesothelioma, respectively, while it was 11.67 months and 25.46 months in cases with epithelial mesothelioma, respectively. Pathological subtype was found to be an effective prognostic factor for both survival (p=0.049 and p<0.001, respectively).

  Conclusion: Hyperthermic intrathoracic chemotherapy following cytoreductive surgery is a preferable and tolerable method in the treatment of malignant pleural mesothelioma. While evaluating surgical indications, it should be kept in mind that cases with epithelial mesothelioma may benefit more from surgical treatment.

  Copyright © 2023, Turkish Society of Cardiovascular Surgery.

• The prognostic value of 18F-fluorodeoxyglucose positron emission tomography/ computed tomography parameters in patients with malignant pleural mesothelioma. B.M. Yenigün, Y. Kahya, Ç. Soydal, et al. 2021;29(1):92-100. PubMed · Publisher · Free full text

  Abstract

  Background: In this study, we aimed to investigate the prognostic value of metabolic 18F-fluorodeoxyglucose positron emission tomography/computed tomography parameters in malignant pleural mesothelioma patients.

  Methods: A total of 65 patients with malignant pleural mesothelioma (34 males, 31 females; median age: 60 years; range, 39 to 84 years) who underwent whole-body 18F-fluorodeoxyglucose positron emission tomography/computed tomography for staging before treatment between March 2008 and January 2018 were included. Relationships between clinicopathological factors and 18F-fluorodeoxyglucose positron emission tomography/computed tomography parameters and overall survival were evaluated using a log-rank test and Cox regression analysis.

  Results: The median follow-up was 13 (range, 4 to 55) months. The Kaplan-Meier analysis revealed a mean survival time of 17±2.6 months. The cumulative two- and five-year survival rates were 34.8% and 7.8%, respectively. Univariate analysis showed that ≥60 age, left hemithorax involvement, a maximum standardized uptake value of ≥9.8, c-T4 status, c-M1 status, and non-surgery were negatively associated with overall survival (p<0.05). Multivariate analysis showed that ≥60 age, left hemithorax involvement, a maximum standardized uptake value of ≥9.8, c-M1 status, and a total lesion glycolysis of ≥180.2 g were negatively associated with overall survival (p<0.05).

  Conclusion: Metabolic parameters of 18F-fluorodeoxyglucose positron emission tomography/computed tomography have the potential to provide prognostic information for malignant pleural mesothelioma patients who are receiving surgery and/or chemotherapy.

  Copyright © 2021, Turkish Society of Cardiovascular Surgery.

2010s

• Comparison of serum biochemical markers in patients with mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos. İ. Döngel, A. Akbaş, İ. Benli, et al. 2019;27(3):374-380. PubMed · Publisher · Free full text

  Abstract

  Background: In this study, we aimed to compare serum biochemical markers in patients with malignant pleural mesothelioma and pleural plaques versus healthy individuals exposed to environmental asbestos.

  Methods: Between September 01, 2010 and March 31, 2011, a total of 540 participants (354 males, 186 females; mean age 61.4 years; range, 35 to 89 years) were included in the study. The participants were divided into four groups as follows: (1) patients with pleural plaques (n=277); (2) healthy individuals with normal chest X-rays who were exposed to environmental asbestos (n=121); (3) healthy individuals with normal chest X-rays who were not exposed to environmental asbestos (n=118); and (4) patients with malignant pleural mesothelioma (n=24). Serum levels of carcinoembryonic antigen, cancer antigen 125, 15-3, 19-9, free T3, free T4, thyroidstimulating hormone, vitamin B12, folate, and ferritin were measured.

  Results: Serum cancer antigen 125, 15-3, folic acid, vitamin B12, and ferritin levels were higher with lower free T3 levels in Group 4 than the other groups. The areas under the curve for cancer antigen 125 and 15-3 were 0.78 and 0.67, respectively in the differential diagnosis of mesothelioma from other pathologies (p<0.001 for both). Optimal limits of these biomarkers were 13.63 and 18.43 ng/mL, respectively with 83% and 75% sensitivity and 69% and 48% specificity, respectively.

  Conclusion: The combination or individual use of serum cancer antigen 125, 15-3, folic acid, vitamin B12, and ferritin levels may be helpful for early diagnosis and treatment of malignant pleural mesothelioma.

  Copyright © 2019, Turkish Society of Cardiovascular Surgery.

Browse every journal in the library or the library by type of article, or return to medical research.